This review systematically examines the pathophysiological mechanisms of the PD-1/PD-L1 pathway in myocardial infarction, explores its potential as a therapeutic target, and assesses the adverse cardiovascular reactions associated with existing immune checkpoint inhibitors and management strategies. This evidence concerns the gene CD274 and myocardial infarction.